Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

Just ahead of sched­ule the FDA has come through with a key ap­proval for Genen­tech’s tu­mor ag­nos­tic en­trec­tinib — now head­ed to the mar­ket as Ro­z­lytrek.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.